Imatinib Mesylate
Information
- Drug Name
- Imatinib Mesylate
- Description
- Entry(CIViC)
- 72
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3-p210BCR-ABL1 cell li... | ABL1 |
ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu403Met (p.L403M) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this in vitro study, the H2110 non-small cell l... | ABL1 |
ABL1 p.Gly340Leu (p.G340L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly340Leu (p.G340L) ( ENST00000318560.6, ENST00000372348.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, Chinese hamster ovary cells ... | PDGFRA |
PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V) ( ENST00000257290.10 ) PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V) ( ENST00000257290.10 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, Chinese hamster ovary cells ... | PDGFRA |
PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A ( ENST00000257290.10 ) PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A ( ENST00000257290.10 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| In an in vitro study, Chinese hamster ovary cells ... | KIT |
KIT p.Val561Asp (p.V561D) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this open-label, phase II registration trial, p... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 |
ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations in the ... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this open-label, phase II registration trial, p... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this open-label, phase II registration trial, p... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe330Leu (p.F330L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Pro (p.H415P) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Arg (p.L267R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln271His (p.Q271H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asp295Gly (p.D295G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, stochastic mutations were in... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this open-label, phase II registration trial, p... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this open-label, phase II registration trial, p... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Cys494ValfsTer8 (p.C494Vfs*8) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Asn355Ser (p.N355S) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu472Ala (p.E472A) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val318Leu (p.V318L) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gln319Arg (p.Q319R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Ile (p.F378I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu274Val (p.E274V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 | ABL1 p.Phe505Ser (p.F505S) ABL1 p.Phe505Ser (p.F505S) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.His415Arg (p.H415R) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 39 chronic phase CML patients with B... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Val398Ile (p.V398I) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 | ABL1 p.Ala416Pro (p.A416P) ABL1 p.Ala416Pro (p.A416P) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Cys (p.F378C) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu374Gly (p.E374G) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met370Thr (p.M370T) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 | ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 | ABL1 p.Glu274Lys (p.E274K) ABL1 p.Glu274Lys (p.E274K) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Tyr272His (p.Y272H) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Gly269Glu (p.G269E) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Met263Val (p.M263V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Phe378Val (p.F378V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Leu267Val (p.L267V) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 | ABL1 p.Phe336Leu (p.F336L) ABL1 p.Phe336Leu (p.F336L) | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II study of 60 imatinib-resistant patie... | ABL1 |
ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) ABL1 p.Glu478Lys (p.E478K) ( ENST00000318560.6, ENST00000372348.9 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01742299 | Active, not recruiting | Phase 4 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | March 26, 2013 | April 21, 2033 |
| NCT01085617 | Active, not recruiting | Phase 3 | Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 2010 | December 2025 |
| NCT00070499 | Active, not recruiting | Phase 2 | Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia | August 15, 2004 | February 22, 2025 |
| NCT04416750 | Active, not recruiting | Phase 2 | Positioning Imatinib for Pulmonary Arterial Hypertension | January 20, 2021 | July 1, 2024 |
| NCT00006343 | Completed | Phase 3 | STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | June 2000 | March 2007 |
| NCT00006357 | Completed | Phase 1/Phase 2 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | August 2000 | |
| NCT00006475 | Completed | Phase 2 | STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis | September 2000 | December 2002 |
| NCT00002514 | Completed | Phase 3 | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | May 7, 1993 | |
| NCT00010049 | Completed | Phase 1/Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma | February 27, 2001 | August 15, 2006 |
| NCT00015834 | Completed | Phase 1/Phase 2 | STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | May 2001 | |
| NCT00015860 | Completed | Phase 1/Phase 2 | STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia | May 2001 | October 2003 |
| NCT04006769 | Completed | Early Phase 1 | Entacapone Combination With Imatinib for Treatment of GIST | October 30, 2020 | August 31, 2022 |
| NCT03023046 | Completed | Phase 2 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | February 23, 2017 | May 1, 2022 |
| NCT00022737 | Completed | Phase 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | October 2002 | |
| NCT00025246 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery | September 2001 | |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00026169 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure | September 2001 | |
| NCT00028002 | Completed | Phase 2 | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor | March 31, 2002 | January 28, 2009 |
| NCT02712112 | Completed | Phase 2 | A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs | March 16, 2016 | June 15, 2019 |
| NCT00030394 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | September 2002 | |
| NCT00030667 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood | May 2002 | December 2005 |
| NCT00031915 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma | June 2002 | May 2007 |
| NCT00036738 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | July 13, 2001 | May 2018 |
| NCT00036751 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | April 2002 | |
| NCT00038194 | Completed | Phase 1 | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer | October 2001 | September 2005 |
| NCT00038610 | Completed | Phase 2 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | March 2001 | July 2014 |
| NCT00039364 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Gliomas | March 2002 | |
| NCT00039377 | Completed | Phase 2 | Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2002 | February 2014 |
| NCT00039416 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | April 2002 | |
| NCT00039585 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | May 2002 | |
| NCT00041041 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | June 2002 | |
| NCT00041197 | Completed | Phase 3 | Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery | June 2002 | |
| NCT00041340 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer | May 2002 | |
| NCT02303899 | Completed | Phase 2 | Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma | November 2014 | December 2017 |
| NCT00045188 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer | August 2002 | |
| NCT00045422 | Completed | Phase 2 | Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | April 2002 | October 2003 |
| NCT00045604 | Completed | Phase 1 | Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | July 2002 | |
| NCT00045669 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Salivary Gland Cancer | July 2002 | January 2005 |
| NCT00045734 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent Meningioma | February 2003 | December 2009 |
| NCT00049127 | Completed | Phase 1/Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor | June 2003 | September 1, 2019 |
| NCT00049192 | Completed | Phase 2 | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | November 2002 | |
| NCT00049569 | Completed | N/A | Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | January 2003 | |
| NCT00052494 | Completed | Phase 1 | Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | April 2003 | |
| NCT00052949 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer | May 2003 | |
| NCT00053248 | Completed | Phase 1/Phase 2 | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | October 2002 | June 2005 |
| NCT00054431 | Completed | Phase 2 | Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | January 2003 | |
| NCT00055874 | Completed | Phase 3 | Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | June 2002 | March 31, 2017 |
| NCT00061945 | Completed | Phase 1/Phase 2 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | June 2003 | October 2012 |
| NCT00062205 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor | June 2002 | June 2007 |
| NCT00064285 | Completed | Phase 1 | Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer | June 2003 | |
| NCT00066326 | Completed | Phase 1 | Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | June 2003 | September 2005 |
| NCT00068380 | Completed | Phase 2 | A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer | March 2004 | March 2010 |
| NCT00068783 | Completed | Phase 2 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | October 2003 | |
| NCT00074308 | Completed | Phase 1/Phase 2 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | October 2003 | July 2009 |
| NCT00075400 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | January 2004 | July 2010 |
| NCT00080665 | Completed | Phase 1 | Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer | December 2003 | January 2011 |
| NCT00080678 | Completed | Phase 2 | Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases | May 2003 | March 2008 |
| NCT00081133 | Completed | Phase 1/Phase 2 | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | December 2003 | February 2005 |
| NCT00084513 | Completed | Phase 1 | Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer | August 2004 | March 2007 |
| NCT00084630 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans | May 2004 | |
| NCT00084825 | Completed | Phase 2 | Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 | May 2003 | June 2008 |
| NCT00085475 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma | April 2004 | |
| NCT00087152 | Completed | Phase 2 | S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer | June 2004 | December 2008 |
| NCT00090987 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma | June 2005 | December 2009 |
| NCT02257541 | Completed | Phase 1/Phase 2 | BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | October 2, 2014 | March 25, 2019 |
| NCT00093639 | Completed | Phase 1/Phase 2 | Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | August 2004 | August 2006 |
| NCT01781975 | Completed | Phase 2 | Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus | January 2014 | May 2018 |
| NCT00103168 | Completed | Phase 3 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | December 2004 | September 2017 |
| NCT00110058 | Completed | Phase 2 | Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia | February 2005 | July 2006 |
| NCT00112632 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor | February 2005 | |
| NCT01738139 | Completed | Phase 1 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | February 19, 2013 | December 13, 2023 |
| NCT00116935 | Completed | Phase 3 | Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | February 2004 | December 2010 |
| NCT01578213 | Completed | Phase 4 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients | November 9, 2011 | November 28, 2018 |
| NCT00136409 | Completed | Phase 2 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | May 2002 | December 2008 |
| NCT00154349 | Completed | Phase 2 | Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia | October 2003 | February 2007 |
| NCT00154375 | Completed | Phase 3 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | October 2004 | |
| NCT00154388 | Completed | Phase 2 | Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases | February 2001 | January 2007 |
| NCT00161213 | Completed | Phase 2 | Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer | September 2005 | October 2010 |
| NCT00171158 | Completed | Phase 2 | An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis | July 26, 1999 | April 22, 2013 |
| NCT01483014 | Completed | Phase 2 | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) | June 2008 | January 2012 |
| NCT00171899 | Completed | Phase 4 | Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) | April 2005 | June 2007 |
| NCT00171912 | Completed | Phase 2 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | September 2004 | January 2012 |
| NCT01309997 | Completed | Phase 2 | Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease | March 2011 | December 2015 |
| NCT00171977 | Completed | Phase 4 | Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) | July 2004 | |
| NCT00216112 | Completed | Phase 2 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | December 2003 | July 2007 |
| NCT00219726 | Completed | Phase 2 | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | May 2002 | July 2007 |
| NCT00237172 | Completed | Phase 2 | Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) | September 2002 | |
| NCT00237185 | Completed | Phase 2 | A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene | June 2000 | June 2013 |
| NCT00243191 | Completed | Phase 2 | Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans | May 2006 | September 2009 |
| NCT00244829 | Completed | Phase 1/Phase 2 | Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | January 2004 | August 2007 |
| NCT01297777 | Completed | Phase 4 | Imatinib in KIT-negative Systemic Mastocytosis | January 2011 | August 2015 |
| NCT00253565 | Completed | Phase 1 | Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors | August 2003 | July 2010 |
| NCT00258271 | Completed | Phase 1 | Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | March 2005 | October 2006 |
| NCT00268229 | Completed | Phase 1 | Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | July 2003 | August 2011 |
| NCT01281865 | Completed | Phase 1/Phase 2 | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | January 2011 | October 2013 |
| NCT00287846 | Completed | Phase 1/Phase 2 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | September 2004 | June 2010 |
| NCT01267695 | Completed | Phase 2 | Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor | May 2010 | October 2014 |
| NCT00301093 | Completed | Phase 1 | Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | September 2005 | September 10, 2020 |
| NCT01172548 | Completed | Phase 2 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) | August 2008 | March 2014 |
| NCT01097694 | Completed | Phase 2 | Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) | November 2010 | August 2016 |
| NCT01083589 | Completed | Phase 2 | Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | January 2005 | July 2011 |
| NCT00327678 | Completed | Phase 3 | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | May 2006 | April 2014 |
| NCT00331409 | Completed | Phase 2 | Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | January 2006 | January 2010 |
| NCT00338728 | Completed | Phase 2 | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | October 3, 2003 | November 27, 2018 |
| NCT00354068 | Completed | Phase 1 | Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma | July 2004 | November 2008 |
| NCT00354913 | Completed | Phase 2 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | May 2005 | October 2010 |
| NCT01011075 | Completed | Phase 2 | Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | August 2009 | July 2012 |
| NCT00386373 | Completed | N/A | Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | August 2003 | October 2007 |
| NCT00387933 | Completed | Phase 1 | Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma | July 2005 | |
| NCT00401024 | Completed | Phase 1 | Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma | October 12, 2006 | November 11, 2008 |
| NCT00402766 | Completed | Phase 1 | Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | August 2006 | February 2014 |
| NCT00408460 | Completed | Phase 2 | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | February 2006 | October 2012 |
| NCT00425646 | Completed | Phase 2 | Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | November 2006 | July 2009 |
| NCT01003054 | Completed | Phase 2 | Autologous Transplantation for Chronic Myelogenous Leukemia | March 2005 | October 2009 |
| NCT00427999 | Completed | Phase 2 | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer | February 2007 | August 2015 |
| NCT00430066 | Completed | Phase 2 | Effects of Imatinib Mesylate in Polycythemia Vera | February 2007 | September 2012 |
| NCT00446004 | Completed | Phase 1 | Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers | April 2007 | August 2009 |
| NCT00455559 | Completed | Phase 2 | Ph II Study of Perifosine Plus Gleevec for Patients With GIST | August 2006 | October 2011 |
| NCT00458848 | Completed | Phase 2 | Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia | October 2004 | March 2014 |
| NCT00470470 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | April 2007 | October 2014 |
| NCT00477269 | Completed | Phase 2/Phase 3 | Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension | April 2006 | January 2014 |
| NCT00479934 | Completed | Phase 2 | Efficacy and Safety of Imatinib in Scleroderma | December 2007 | December 2010 |
| NCT00483366 | Completed | Phase 1 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | August 15, 2006 | March 29, 2011 |
| NCT00485485 | Completed | Phase 2 | Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | January 2007 | March 2010 |
| NCT00928525 | Completed | Phase 2 | Imatinib in Patients With Desmoid Tumor and Chondrosarcoma | May 2007 | December 2018 |
| NCT00500110 | Completed | Phase 2 | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | June 2003 | February 2010 |
| NCT00902174 | Completed | Phase 3 | Imatinib (QTI571) in Pulmonary Arterial Hypertension | September 2009 | May 2011 |
| NCT00506831 | Completed | Phase 1/Phase 2 | Imatinib in Systemic Sclerosis | July 2007 | September 2010 |
| NCT00509093 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy | October 2008 | April 9, 2015 |
| NCT00510354 | Completed | Phase 4 | Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate | October 2006 | November 2012 |
| NCT00510653 | Completed | Phase 2 | Gleevec Study for Patients With Ovarian Cancer | March 2002 | February 2012 |
| NCT00555581 | Completed | Phase 2 | Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis | August 2007 | December 2011 |
| NCT00867113 | Completed | Phase 2 | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | July 22, 2009 | December 20, 2016 |
| NCT00769327 | Completed | Phase 2 | Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | February 9, 2009 | October 10, 2014 |
| NCT00601510 | Completed | Phase 1 | Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer | November 2007 | January 2012 |
| NCT00618501 | Completed | Phase 2 | Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | October 2005 | January 2009 |
| NCT00677092 | Completed | Phase 2 | Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis | December 2007 | July 2009 |
| NCT00684411 | Completed | Phase 2 | Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | June 2008 | October 2013 |
| NCT00764595 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor | October 2008 | March 2016 |
| NCT00686218 | Completed | Phase 1 | Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia | May 2008 | August 2014 |
| NCT00702403 | Completed | Phase 1/Phase 2 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | August 14, 2008 | December 1, 2013 |
| NCT00763763 | Completed | Phase 2 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | December 2004 | January 2010 |
| NCT00732784 | Completed | Phase 1 | Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers | November 2008 | December 2012 |
| NCT00004932 | Completed | Phase 1 | STI571 in Treating Patients With Recurrent Leukemia | January 2002 | September 2005 |
| NCT00006052 | Completed | Phase 2 | STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia | June 2000 | |
| NCT00006053 | Completed | Phase 2 | STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | June 2000 | March 2003 |
| NCT05970900 | Not yet recruiting | Phase 3 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST | October 1, 2023 | October 1, 2029 |
| NCT04488081 | Recruiting | Phase 2 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | July 31, 2020 | July 31, 2030 |
| NCT03007147 | Recruiting | Phase 3 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | August 8, 2017 | September 30, 2027 |
| NCT05385549 | Recruiting | Phase 2 | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | September 7, 2022 | April 30, 2030 |
| NCT04129931 | Recruiting | Phase 2 | PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study | December 19, 2019 | December 2024 |
| NCT05623774 | Recruiting | Phase 1 | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg | December 16, 2022 | March 31, 2024 |
| NCT03997903 | Recruiting | Phase 1/Phase 2 | Imatinib for Pain in Sickle Cell Anemia | February 26, 2020 | September 2025 |
| NCT03516279 | Recruiting | Phase 2 | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | June 26, 2019 | August 31, 2031 |
| NCT01222013 | Suspended | Phase 2 | Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | ||
| NCT01005914 | Terminated | Phase 2 | Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | June 2009 | May 2014 |
| NCT00372567 | Terminated | Phase 3 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | June 2007 | November 2009 |
| NCT01031628 | Terminated | Phase 3 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | January 2010 | June 2011 |
| NCT00324987 | Terminated | Phase 3 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | April 2008 | July 2015 |
| NCT00323791 | Terminated | Phase 2 | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | April 2006 | August 2007 |
| NCT00323362 | Terminated | Phase 2 | Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer | April 2006 | October 2008 |
| NCT00323063 | Terminated | Phase 2 | Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer | May 1, 2006 | June 20, 2016 |
| NCT00281996 | Terminated | Phase 1 | Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer | March 2005 | October 2008 |
| NCT00245128 | Terminated | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | August 2005 | October 2011 |
| NCT00171938 | Terminated | Phase 2 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) | April 2004 | June 2006 |
| NCT01312818 | Terminated | Phase 2 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | June 2011 | January 2013 |
| NCT01383447 | Terminated | Phase 1/Phase 2 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | October 2010 | April 2012 |
| NCT00171860 | Terminated | Phase 2 | A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome | September 2002 | |
| NCT01545427 | Terminated | Phase 2 | Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma | April 2008 | December 2008 |
| NCT00124748 | Terminated | Phase 3 | Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) | June 2005 | November 2010 |
| NCT00114959 | Terminated | Phase 2 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | October 2005 | March 2009 |
| NCT01751425 | Terminated | Phase 1 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | July 24, 2013 | September 24, 2019 |
| NCT00101088 | Terminated | Phase 1 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | April 2005 | |
| NCT01827930 | Terminated | Phase 3 | Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response | July 2009 | January 1, 2017 |
| NCT02177825 | Terminated | Phase 2 | Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas | June 2014 | March 1, 2019 |
| NCT00091078 | Terminated | Phase 2 | Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery | September 2005 | |
| NCT00042952 | Terminated | Phase 2 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | June 2002 | |
| NCT00009906 | Terminated | Phase 3 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | December 2000 | November 2014 |
| NCT00861471 | Terminated | Phase 1/Phase 2 | Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | May 2005 | May 2010 |
| NCT00573404 | Terminated | Phase 1 | Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors | July 2007 | March 2011 |
| NCT00882206 | Terminated | Phase 2 | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | April 2009 | January 2013 |
| NCT00506779 | Terminated | Phase 1/Phase 2 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | December 29, 2003 | April 2015 |
| NCT00499889 | Terminated | Phase 2 | Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | February 2003 | November 2009 |
| NCT00956072 | Terminated | Phase 3 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | May 2009 | |
| NCT00427583 | Terminated | Phase 2/Phase 3 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | May 2006 | |
| NCT02644525 | Terminated | Phase 2 | Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa | September 16, 2019 | March 19, 2021 |
| NCT02709083 | Terminated | Phase 2 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | October 2016 | July 2018 |
| NCT00022490 | Terminated | Phase 2 | Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia | June 2001 | July 2011 |
| NCT00021229 | Terminated | Phase 1/Phase 2 | Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma | May 2001 | August 2008 |
| NCT00015847 | Terminated | Phase 2 | Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | April 2001 | May 2011 |
| NCT03241199 | Unknown status | Phase 2 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | August 1, 2017 | January 1, 2021 |
| NCT01005758 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 2009 | |
| NCT02687425 | Unknown status | Phase 2 | Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia | February 2016 | June 2017 |
| NCT00290485 | Unknown status | Phase 2 | Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) | August 2005 | |
| NCT00028847 | Unknown status | Phase 1/Phase 2 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | April 2001 | |
| NCT03674099 | Unknown status | Phase 2 | Imatinib for Multiple Sclerosis (MS) Relapses | October 1, 2018 | July 30, 2023 |
| NCT00112775 | Unknown status | Phase 2 | BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | March 2005 | |
| NCT01227135 | Unknown status | Phase 2 | Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | March 2010 | |
| NCT00904735 | Unknown status | Phase 2 | Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma | June 2009 | |
| NCT01221376 | Unknown status | Phase 2 | Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) | February 2011 | December 2013 |
| NCT00685828 | Unknown status | Phase 3 | Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor | January 2001 | |
| NCT04422678 | Unknown status | Phase 3 | The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia | June 2020 | October 2020 |
| NCT00594555 | Withdrawn | Phase 2 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | November 2007 | November 2008 |
| NCT03688568 | Withdrawn | Phase 2 | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | September 1, 2018 | September 1, 2021 |
| NCT02812693 | Withdrawn | Phase 1/Phase 2 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | November 4, 2016 | November 20, 2017 |
| NCT02538926 | Withdrawn | Phase 2 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | July 1, 2018 | July 30, 2021 |
| NCT04953052 | Withdrawn | Phase 2 | A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care. | October 14, 2021 | November 30, 2022 |